Quantcast
Home > Quotes > MYOK

MyoKardia, Inc. Common Stock (MYOK) Quote & Summary Data

MYOK 
$48.1
*  
0.60
1.23%
Get MYOK Alerts
*Delayed - data as of Jun. 19, 2018  -  Find a broker to begin trading MYOK now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MYOK Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
73
Today's High / Low
$ 48.55 / $ 47.35
Share Volume
336,127
50 Day Avg. Daily Volume
371,850
Previous Close
$ 48.70
52 Week High / Low
$ 62.83 / $ 12.60
Market Cap
1,729,967,534
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.54
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.5

Intraday Chart

Shares Traded

Share Volume:
336,127
50 Day Avg. Daily Volume:
371,850

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.54

Trading Range

The current last sale of $48.10 is 281.75% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 48.55 $ 62.83
 Low: $ 47.35 $ 12.60

ETFs with MYOK as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.53% SPDR S&P Pharmaceuticals ETF (XPH) -1.90 (-4.11%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

MyoKardia, Inc. (the "Company"), incorporated under the laws of the State of Delaware in 2012, is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to discover and develop a pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy--hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM, both of which are chronic and debilitating diseases. Our proprietary, orally administered small molecules target the biomechanical defects that cause disruptions in heart muscle contraction.  ... More ...  

Risk Grade

Where does MYOK fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 48.10
Open Date:
Jun. 19, 2018
Close Price:
$ 48.70
Close Date:
Jun. 19, 2018

Consensus Recommendation

Analyst Info